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The combination of selected fibrinolytic and coagu-Abstract
lation measurements is useful for the detection of
a hypercoagulable state in conditions character-Hypercoagulable states can be detected by mea-
ized by a risk of thrombosis.  1999 Elsevier Sci-suring activation peptides, enzyme-inhibitor com-
ence Ltd. All rights reserved.plexes, and fibrin/fibrinogen degradation products,
which are markers of hemostatic activation. A se-
ries of these prethrombotic markers has been eval- Key Words: Hypercoagulability; Elderly; Pregnancy; Dia-
betes; Myocardial infarction; Malignancyuated in the elderly, pregnancy, diabetes and acute
myocardial infarction patients (n530 in each group)
as well as in hematologic malignancies (n542). The Aprethrombotic state may be defined as aparameters assayed were: prothrombin fragment condition characterized by an imbalance112 (F112), thrombin-antithrombin III complexes in hemostasis with a tendency to hyper-
(TAT), fibrinopeptide A (FPA), plasmin-a2 anti- coagulability, due to pathological activation of the
plasmin complexes (PAP) and D-Dimer. Results enzymes of the coagulation cascade, but without
were compared with those obtained in a group of clinical signs of thrombosis or evidence of fibrin
30 healthy subjects. deposition [1]. Hypercoagulable states can be clas-
We found a significant increase of F112, TAT sified into two broad categories: congenital and
and FPA in elderly (p,0.05), acute myocardial acquired. The former are generally inherited ab-
infarction (AMI) (p,0.01), hematologic malignan- normalities of hemostasis clearly identified, while
cies (p,0.01), and pregnancy (p,0.0001), indicat- acquired hypercoagulable states include clinical con-
ing a marked clotting activation. Diabetic patients ditions associated with an increased risk of throm-
under strict metabolic control only presented a mod- bosis in whom the exact pathophysiologic mecha-
erate increase of TAT (p,0.05), suggesting a slight nism remains unclear [2,3].
activation. We also observed a highly significant ele- The importance of detecting these prethrom-
vation of PAP and D-Dimer in elderly (p,0.001), botic states deals with the possibility to diminish
AMI (p,0.0001), and malignancy (p,0.0001), in- the thrombotic tendency by treating or eliminating
dicating an activation of the fibrinolytic system. the responsible factors. Advances in our knowl-
edge of the biochemistry of the hemostatic mecha-
nism have allowed the development of sensitiveAbbreviations: F112, prothrombin fragment 112; TAT, throm-
bin-antithrombin complex; PAP, plasmin-antiplasmin complex; and specific assays to detect activation of coagula-
FPA, fibrinopeptide A; AMI, acute myocardial infarction. tion and fibrinolysis in vivo [4,5]. Among them
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when activated to their corresponding enzymes, the analgesic drugs during the week before the inclu-
sion in the study.fibrinogen/fibrin degradation products, released by
the action of plasmin, and the enzyme-inhibitor
complexes, which have a longer half-life in contrast 1.2. Blood Collection
to their precursor molecules, emerge as sensitive
prethrombotic markers [6]. Blood samples were collected in the morning, with
Previous studies analyzing the integrity of the patients at rest, in siliconized vacutainer tubes con-
hemostatic system in prethrombotic states do not taining 1:10 of 0.13 M trisodium citrate. Samples
offer a complete perspective since, in general, only were kept on ice until centrifugation at 3000g for
individual components have been assessed. The aim 15 minutes, performed within the first hour after
of our study was to include a complete set of pre- collection. Aliquots of platelet-poor plasma were
thrombotic markers in a series of clinical conditions stored at 2708C.
characterized by a high thrombotic tendency.
1.3. Assays
1. Patients and Methods Prothrombin fragment 112 (F112), was assayed
using the commercial Enzygnost(R) F112 Kit (Beh-
1.1. Patients ringwerke AG, Germany) [7]. Thrombin-anti-
thrombin III complexes (TAT) were measured
The study included 162 patients divided into the using the ELISA Kit Enzygnost(R) TAT (Beh-
following categories: advanced age (n530), preg- ringwerke AG, Germany) [8]. Fibrinopeptide A
nancy (n530), diabetes (n530), acute myocardial (FPA) was measured with the ELISA FPA Kit
infarction (n530), and hematologic malignancies (Hemodiagnostica-Stago, Asnieres, France), which
(n542). A control group consisted of 30 healthy is a competitive enzyme immunoassay [9]. Plasmin-
subjects. a2-antiplasmin complexes (PAP) were measured
with the commercial ELISA Kit EIA APP microElderly people, with an age over 65 years, who
(Berhingwerke AG, Marburg, Germany) [10].presented no other known risk factors were in-
D-Dimer levels were measured with the Fibrinos-cluded in the advanced age group (mean age5
tiKa FbDP Kit (Organon Teknika, Turnhout, Bel-70.7 64.4 years, male/female520:10). The preg-
gium), which incorporates a specific monoclonalnancy group included 30 women in the third
antibody anti–D-Dimer [11].trimester of uncomplicated gestation (mean age5
34.463.3 years). Diabetic patients were under met-
abolic control and presented no signs of retino- 1.4. Statistical Analysis
pathy, neuropathy or nephropathy (mean age5
54.3615.2 years, male/female: 12:18). Patients with Data was statistically described using mean values,
standard deviation (SD) and standard error of themyocardial infarction (AMI) were studied during
the first week from the onset of diagnosis (mean mean (SEM). Values were tested for the type of
distribution using Kolmogorov-Smirnov test. Asage5 61.3610.6 years, male/female518:12); all pa-
tients were receiving aspirin (250 mg/d) and hepa- the parameters followed a not normal distribution
the median was also assessed. Statistical analysisrin (7500 IU) subcutaneously twice daily. A group
of 42 patients with hematologic malignancies were was done with the two-tail Mann-Whitney U test
for comparison of median of impaired data. Corre-studied during the active phase of the disease, be-
fore chemotherapy (mean age547.3617.6 years; lations were calculated using Spearman’s rank test.
A value of p,0.05 was considered to be significant.male/female525:17). Malignancies included: Hodg-
kin’s disease (n511), non Hodgkin’s lymphoma
(n58), myeloma (n511), and acute leukemia
(n512). Subjects included in the control group 2. Results
(mean age545.369.15 years; male/female519:11)
did not present any known thrombotic risk factor The plasma levels of selected coagulation and fibri-
nolysis markers were measured in 162 patients,and had not taken neither anti-inflammatory nor
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with a variety of clinical conditions known to be 2.4. Acute Myocardial Infarction (AMI)
associated with an increased thrombotic tendency.
Plasma samples from 30 patients who had sufferedIndividual distribution of data, according to differ-
a myocardial infarction were drawn within a weekent patients categories, is shown in Figures 1 and
after the acute episode. The levels of all clotting2, whereas the mean values are reported in Table 1.
markers were significantly elevated as compared
to the control group (Table 1 and Figure 1). TAT2.1. Elderly People
correlated significantly with F112 (r50.81;
p,0.0001) and with FPA levels (r50.48; p,0.05).The study included 30 healthy subjects over the
F112 also correlated with FPA (r50.39; p,0.05).age of 65. As shown in Table 1, the levels of F112
Among the fibrinolytic parameters, PAP com-(p,0.0001), TAT (p,0.05), and FPA (p,0.01)
plexes and D-Dimer were significantly increasedwere elevated in relation to values observed in the
with respect to controls (p,0.0001) (Table 1 andcontrol group (Figure 1 and Table 1). A correlation
Figure 2). A positive correlation between PAP andof FPA with F112 (r50.42; p,0.05) and TAT
D-Dimer (r50.73; p,0.001) was observed. Finally,(r50.55; p,0.01) was found.
D-Dimer correlated significantly with both F112A marked increase of PAP complexes (p,0.0001)
(r50.66; p,0.01) and TAT (r50.61; p,0.01), andand D-Dimer generation (p,0.01) was also ob-
PAP levels also correlated with F112 (r50.63;
served (Figure 2). Besides, D-Dimer levels corre- p,0.01) and TAT (r50.49; p,0.05).
lated with F112 (r50.49; p,0.01), TAT (r50.46;
p,0.05), and FPA (r50.45; p,0.05). 2.5. Hematologic Malignancies
2.2. Pregnancy Forty-two patients with different hematologic ma-
lignancies were included. As shown in Figure 1,
Thirty healthy pregnant women in the third ges- the levels of all clotting markers, mainly TAT,
tational trimester were included in the study. As increased significantly in relation to controls
shown in Figure 1 and Table 1, we found a sig- (p,0.0001) and a correlation between TAT and
nificant increase of F112, TAT, and FPA in rela- F112 (r50.60; p,0.01) was observed.
tion to the levels obtained in the control group The levels of PAP complexes and D-Dimer were
also very significantly increased in relation to the(p,0.0001). A correlation between F112 and TAT
values observed in the control group (p,0.0001).(r50.51; p,0.01) was observed. TAT complexes
A positive correlation between PAP and D-Dimeralso correlated with D-Dimer levels (r50.61;
(r50.72; p,0.0001) was observed. D-Dimer levelsp,0.001).
also correlated with TAT (r50.64; p,0.0001) andAmong the fibrinolytic parameters, D-Dimer
F112 (r50.55; p,0.01), while PAP correlated onlylevels were significantly increased (p,0.0001) and
with TAT levels (r50.55; p,0.01).PAP complexes (p,0.05) were lower than in the
The hemostatic activation was significantly highercontrol group (Figure 2). A significant correlation
in patients with acute leukemia as compared tobetween PAP and D-Dimer (r50.41; p,0.05) was
lymphoproliferative disorders: F112 (3.0560.71observed.
vs. 1.5060.11), TAT (19.3765.49 vs. 6.3561.15),
FPA (3.4260.66 vs. 1.8560.26), PAP (1924.1762.3. Diabetes Mellitus
478.48 vs. 736.00665.46), and D-Dimer (6439.006
2547.05 vs. 1381.006200.50), though significance
Thirty patients with diabetes mellitus under strict (p,0.05) was only reached for TAT, FPA, and
metabolic control were included. Whereas there PAP levels due to the wide data dispersion.
was a trend for a TAT increase (p,0.05), F112
and FPA levels showed no significant differences
in relation to control (Table 1). We also found a 3. Discussion
significant increase of PAP complexes (p,0.01),
while the concentration of D-Dimer was within the The assessment of prethrombotic markers may be
useful to elucidate the role of clotting activationnormal range (Figure 2).
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Fig. 1. Individual distribution
of F112 (A), TAT (B), and
FPA (C) in patients and con-
trols.
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and fibrinolysis impairment before the develop- the hemostatic impairment in different clinical con-
ditions characterized by an increased tendencyment of clinical thrombosis. However, previous
studies on hemostasis alterations in hypercoagula- to thrombosis.
In view of the known association between vascu-ble states offer a partial view on the pathophysio-
logical role of coagulation and fibrinolysis mecha- lar complications and advanced age [12,13], we
have analyzed several hemostatic factors in a groupnisms [reviewed in references 1–6]. In this report,
we have included a wide set of prethrombotic of apparently healthy elderly subjects. We found
an activation of the coagulation system as indicatedmarkers to have a more complete information on
Fig. 2. Individual distribution
of PAP (top) and D-Dimer
(bottom) in patients and con-
trols.
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by the increase of F112, TAT, and FPA. Bauer
et al. demonstrated that the increased values of
F112 in elderly patients were due to excessive
production and not to a diminished clearance of
the fragment [14]. We also found that FPA levels
correlated positively with F112 and TAT, sug-
gesting that thrombin formation is accompanied
by an increase in fibrin generation [15]. The corre-
lations between D-Dimer levels and clotting mark-
ers suggest that fibrinolysis could compensate for
the hypercoagulable state in the elderly group.
We found a significant increase of F112, TAT
and FPA in pregnancy, indicating a marked activa-
tion of the coagulation system during the third
trimester of gestation [16]. Some studies have dem-
onstrated that the increase of TAT levels may be
a marker for detecting pregnancies complicated
with hypertension or pre-eclampsia [17,18]. The
observed correlations of TAT levels with F112
and D-Dimer in our study suggest that increased
thrombin formation associated with fibrin genera-
tion is also present in uncomplicated pregnancies
even though PAP complexes decreased. An in-
crease in plasminogen activator inhibitors during
pregnancy [19–21] could account for a reduction
in PAP complex formation.
Diabetes mellitus is often associated with mi-
croangiopathy, atherosclerosis, and an impairment
of the hemostatic system [22]. We found a slight
increase of TAT complexes with normal levels of
F112 and FPA in the diabetic group, indicating a
moderate coagulation activation. Previous studies
have suggested that the clotting impairment in dia-
betes depends on the presence of vascular compli-
cations and on the degree of metabolic regulation,
mainly the glycemic control [23–25]. Our study sup-
ports these observations, since our patients were
under strict metabolic control and had no vascu-
lar complications. On the other hand, despite the
significant elevation of PAP levels, no D-Dimer
increase occurred, and no correlation between both
parameters could be demonstrated, suggesting
that no significant amounts of fibrin have been
generated.
The hemostatic mechanism is known to be acti-
vated in the acute phase of myocardial infarction
[26]. In our study, a significant increase of all clot-
ting activation markers and a positive correlation
among them was present in patients who had suf-
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fered an AMI within 7 days after the onset of symp-
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toms, even though they were under antithrombotic 4. Bauer KA. New markers for in vivo coagula-
tion. Curr Opin Hematol 1994;1:341–6.therapy [27,28]. Our results also showed that, de-
5. Mannucci PM, Giangrande PLF. Detection ofspite the well-known PAI-1 enhancement [29], a
prethrombotic state due to procoagulant im-marked activation of the fibrinolytic system takes
balance. Eur J Haematol 1992;48:65–9.place as a response to the thrombotic occlusion of
6. Boisclair MD, Ireland H, Lane DA. Assess-coronary arteries in AMI [30].
ment of hypercoagulable states by measure-Hypercoagulability coexisted with hyperfibrino-
ment of activation fragments and peptides.lysis in recently diagnosed hematologic malignancy
Blood Rev 1990;4:25–40.patients [31,32]. A marked clotting activation was
7. Pelzer H, Schwarz A, Stuber W. Determinationdemonstrated in the series analyzed, being TAT
of human prothrombin activation fragment 112levels those more significantly elevated. Interest-
in plasma with an antibody against a syntheticingly, TAT, FPA, and PAP levels were significantly
peptide. Thromb Haemost 1991;65:153–9.higher in patients with acute leukemia in relation
8. Pelzer H, Schwarz A, Heimburger N. Determi-to those observed in patients with lymphoprolifera-
nation of human thrombin-antithrombin com-tive syndromes, indicating a stronger hemostatic
plex in plasma with an enzyme-linked immuno-activation in the former group [33,34]. As regards
sorbent assay. Thromb Haemost 1988;59:101–6.the fibrinolytic parameters, PAP and D-Dimer
9. Amiral J, Walenga JM, Fareed J. Developmentwere strongly elevated in more than 80% of malig-
of a competitive enzyme immunoassay for fi-nant patients, indicating an important degree of
brinopeptide A. Sem Thromb Hemost 1984;fibrinolysis activation [35]. The observed correla-
10:228–42.tions with the coagulation markers suggest a fi-
10. Pelzer H, Pilgrim A, Schwarz A, Merte D,brinolytic response to clotting activation in this
Keuper H, Hock H. Determination of a2-anti-particular group of patients [36].
plasmin-plasmin complex in human plasmaOur results emphasize the usefulness of an asso-
with an enzyme-linked immunosorbent assay.ciation of selected fibrinolytic and coagulation
Fibrinolysis 1993;7:69–74.measurements for the detection of a hypercoagula-
11. Koppert PW, Hoegee-de Nobel E, Nieuwen-ble state in different groups of subjects in which
huizen W. A monoclonal antibody-based en-dissimilar triggering mechanisms result in a risk of
zyme immunoassay for fibrin degradationthrombotic events. Testing of the plasma levels of
products. Thromb Haemost 1988;59:310–5.TAT, F112, PAP and D-Dimer in future studies,
12. Mari D, Mannucci PM, Coppola R, Bottassoin larger patients subgroups, seems to be warranted
B, Bauer KA, Rosenberg RD. Hypercoagula-to examine their value for risk stratification in pa-
bility in centenarians: The paradox of success-tients with hypercoagulable states.
ful aging. Blood 1995;85:3144–9.
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